These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31959726)

  • 1. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
    Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
    Front Immunol; 2021; 12():797407. PubMed ID: 35145510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
    Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
    Front Immunol; 2022; 13():902167. PubMed ID: 36003385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 7. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.
    Chen L; Zhu D; Feng J; Zhou Y; Wang Q; Feng H; Zhang J; Jiang J
    Cancer Cell Int; 2019; 19():101. PubMed ID: 31015801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
    Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
    J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
    Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
    Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
    Liao X; Zhang D
    Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.
    Li Y; Yang Q; Yang X; Ge J; Xu T; Liu H
    J Oral Pathol Med; 2024 Feb; 53(2):159-168. PubMed ID: 38321252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
    Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
    Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
    Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
    Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.